Showing posts with label Delivery. Show all posts
Showing posts with label Delivery. Show all posts

Friday, January 3, 2014

In exascale, Japan stands apart with firm delivery plan

Japan intends to deliver an exascale supercomputer in six years. The firm completion date makes Japan novel among the nations in the race to build exascale systems.

The Riken Advanced Institute for Computational Science in Kobe, Japan, already home to that nation's largest computer system, said last week it will lead Japan's exascale program, with "successful development of the exascale supercomputer scheduled for completion by 2020."

"We will devote our energy to this project," said Kimihiko Hirao, director of the Riken institute, in a statement. An exascale system "will be a great boon for science and technology, as well as industry," he said.

Computerworld - Japan intends to deliver an exascale supercomputer in six years. The firm completion date makes Japan novel among the nations in the race to build exascale systems.

The Riken Advanced Institute for Computational Science in Kobe, Japan, already home to that nation's largest computer system, said last week it will lead Japan's exascale program, with "successful development of the exascale supercomputer scheduled for completion by 2020."

"We will devote our energy to this project," said Kimihiko Hirao, director of the Riken institute, in a statement. An exascale system "will be a great boon for science and technology, as well as industry," he said.

The U.S., meanwhile, is aiming for an "early 2020s" delivery of an exascale system , a Dept. of Energy official said during a presentation that coincided with the annual supercomputing conference, SC13, in November.

In December, Congress approved a fiscal 2014 defense budget bill that requires development of an exascale system within a 10-year period, or by 2024. This is an improvement over an earlier Senate defense funding bill that included a "20 year plan."

The Europeans are developing an ARM-based exascale system and have set a delivery goal of 2020. That goal, though, doesn't have the stake-in-the-ground clarity of Japan. China, which presently operates the world's fastest supercomputer according to the Top 500 rankings, is believed to be targeting 2018-2020 timeframe for exascale delivery, but has not yet made an official announcement.

An exascale system is capable of a quintillion, or a million trillion, floating point operations per second. It is approximately 1,000 faster than a single petaflop system. The fastest systems in use today are well under 50 petaflops.

Exascale development may be a race but no one has yet defined what will constitute a winner. Today, the fastest supercomputers are determined by their ranking on the Top 500 list. But if a nation deploys an exascale system that uses 100 MWs of power, and another nation deploys one two years later with technology that uses a third as much power, which nation has won?

It now costs about $1 million a year to run a 1 megawatt system, and current supercomputers are already in the range of 10 megawatts. There are numerous technical challenges to reduce those power requirements.

For instance, memory is a major challenge for exascale developers. DRAM memory is too slow and expensive to support exascale, but scientists aren't sure yet what will replace it.

Along with the race to deliver exascale, another technology competition is taking shape: quantum computing.

The U.K. last month said it is investing $444 million in quantum computing over the next five years. The money will fund a network of quantum computing centers.

"Science is a personal priority of mine," said U.K. Chancellor George Osborne, in a speech last month outlining the quantum computing effort.

Quantum computing uses subatomic particles and has the potential to leapfrog all other forms of computing. Today, computation is based on bits that can be either 0 or 1, with calculations done one after the other. But quantum can hold those states, 0 and 1, simultaneously increasing processing power exponentially.


View the original article here

Wednesday, June 19, 2013

[Research Articles] In Vivo-Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous

Sci Transl Med 12 June 2013:
Vol. 5, Issue 189, p. 189ra76
Sci. Transl. Med. DOI: 10.1126/scitranslmed.3005708 BLINDNESS Deniz Dalkara1,*, Leah C. Byrne1,*, Ryan R. Klimczak2, Meike Visel2, Lu Yin3, William H. Merigan3, John G. Flannery1,2,† and David V. Schaffer1,2,4,†

1Helen Wills Neuroscience Institute, University of California, Berkeley, CA 94720–1462, USA.
2Department of Molecular and Cellular Biology, University of California, Berkeley, CA 94720–1462, USA.
3Flaum Eye Institute and Center for Visual Science, University of Rochester, Rochester, NY 14642, USA.
4Department of Chemical and Biomolecular Engineering, University of California, Berkeley, CA 94720–1462, USA. ?†Corresponding author. E-mail: schaffer{at}berkeley.edu (D.V.S.); flannery{at}berkeley.edu (J.G.F.) ?* These authors contributed equally to this work.

Inherited retinal degenerative diseases are a clinically promising focus of adeno-associated virus (AAV)–mediated gene therapy. These diseases arise from pathogenic mutations in mRNA transcripts expressed in the eye’s photoreceptor cells or retinal pigment epithelium (RPE), leading to cell death and structural deterioration. Because current gene delivery methods require an injurious subretinal injection to reach the photoreceptors or RPE and transduce just a fraction of the retina, they are suitable only for the treatment of rare degenerative diseases in which retinal structures remain intact. To address the need for broadly applicable gene delivery approaches, we implemented in vivo–directed evolution to engineer AAV variants that deliver the gene cargo to the outer retina after injection into the eye’s easily accessible vitreous humor. This approach has general implications for situations in which dense tissue penetration poses a barrier for gene delivery. A resulting AAV variant mediated widespread delivery to the outer retina and rescued the disease phenotypes of X-linked retinoschisis and Leber’s congenital amaurosis in corresponding mouse models. Furthermore, it enabled transduction of primate photoreceptors from the vitreous, expanding its therapeutic promise.

Copyright © 2013, American Association for the Advancement of ScienceCitation: D. Dalkara, L. C. Byrne, R. R. Klimczak, M. Visel, L. Yin, W. H. Merigan, J. G. Flannery, D. V. Schaffer, In Vivo–Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous. Sci. Transl. Med. 5, 189ra76 (2013).


View the original article here